Triptorelin Embonate

Phase 3Small molecule

Ipsen

Triptorelin Embonate is one of 65 small molecule programs targeting Prostate Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

EndometriosisActive, not recruiting

Prostate CancerPhase 3

Active, not recruiting

EndometriosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Triptorelin Embonate

Ipsen

Phase 3

3 2

Mekinist

Novartis

Preclinical

3 3

Trexall

Alnylam Pharmaceuticals

Preclinical

—4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 5

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 6

Prednisone/prednisolone

Roche

Preclinical

3 7

Triptorelin Pamoate

Ipsen

Preclinical

2 8

Osmitrol

BB. Braun Medical Inc.

Preclinical

—9

Ifex

BBaxter Healthcare Corporation

Preclinical

—10

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 3Recruiting

Prostate Cancer

NCT05019846

Q1 2032

Phase 3Recruiting

Chemotherapy

NCT05328258

Clinical

Trials by Indication[1]

Prostate Cancer3 trials

SRT Versus SRT+ADT in Prostate Cancer

Recruiting·MMarco Lorenzo Bonu·Phase 3·NCT05019846·310 enrolled

Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer

Completed·DDebiopharm International SA·Phase 3·NCT01656161·120 enrolled

Efficacy and Safety of a Triptorelin 6-month Formulation in Patients With Advanced Prostate Cancer

Completed·DDebiopharm International SA·Phase 3·NCT00751790·120 enrolled

Endometriosis1 trial

Effect GnRH Agonist Administration in Endometriosis Cyst Patients

Recruiting·RRumah Sakit Pusat Angkatan Darat Gatot Soebroto·Phase 3·NCT06525155·32 enrolled

Prostate1 trial

Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate

Completed· Ipsen logo

Ipsen·Phase 3·NCT05458856·147 enrolled

Chemotherapy1 trial

Use of GnRHa During Chemotherapy for Fertility Protection

Recruiting·KKenny Rodriguez-Wallberg·Phase 3·NCT05328258·500 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Triptorelin Embonate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Triptorelin Embonate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Triptorelin Embonate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ipsen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Ipsen

Triptorelin Embonate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Q1 2032

Trials by Indication[1]

Prostate Cancer3 trials

Endometriosis1 trial

Prostate1 trial

Chemotherapy1 trial

References

Drug Info

Quick Facts

Related News